Optimmune 2 mg/g Eye Ointment for Dogs

Clinical experience has shown that 90% of dogs affected with KCS will require life-long
therapy.
However, if therapy is maintained, the prognosis is good providing that regular clinical
assessment is conducted.
Similarly, chronic superficial keratitis may require continuous therapy although, as the
condition is exacerbated by ultraviolet light, requirement for treatment may be
suspended or reduced at certain times of the year.

Amended Pages: March 2026
AN: 01279/2025Page 2 of 5
In the treatment of KCS, it is important that continuous treatment is maintained.
Studies have shown that stimulation of tear production ceases within 24 hours of
withdrawing treatment. Increase in tear production is expected within 10 days but may
not be maximal until 6 weeks from commencement of treatment.

Special precautions for safe use in the target species:
For external topical use only.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
The veterinary medicinal product may cause skin and eye irritation. Avoid contact with
the skin and eyes.
Personal protective equipment consisting of gloves should be worn when handling the
veterinary medicinal product.
Do not eat, drink or smoke while handling the veterinary medicinal product.
Wash hands and contacted skin thoroughly with soap and water immediately after use
of the veterinary medicinal product.
In case of contact with the eyes, immediately rinse thoroughly with water.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.